Best AAV / Gene Therapy CDMOs in China

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

US sponsors evaluating Chinese CDMOs currently face two active US regulatory considerations. The DoD 1260H list designates named Chinese companies as "Chinese Military Companies" — WuXi AppTec was added in June 2026. Listing itself doesn't restrict commercial pharma work but affects federally-funded research access and creates procurement complications for sponsors with government contracts. The BioSecure Act is proposed federal legislation that would restrict federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies (specifically BGI, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics as of current drafts). The bill has not passed as of 2026-08 but has bipartisan support. CDMO Signal does not encode US political risk into the Signal Score — the composite reflects regulatory quality, operations, financial stability, and capacity. Sponsors evaluating a Chinese CDMO for US-supplying programs should evaluate US regulatory risk separately as a distinct decision layer.

Chinese CDMOs supplying US and European markets need active FDA and EMA GMP certifications on the specific facility. The FDA and EMA both conduct facility inspections in China, and Chinese CDMOs' inspection outcomes have generally improved over the past decade. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Chinese CDMOs with cross-jurisdictional certification rank higher on this pillar than domestic-market-only competitors. Cross-check with the US region ranking — Chinese CDMOs appearing on both rankings have demonstrated cross-jurisdictional inspection posture, which materially reduces regulatory risk for programs supplying US markets.

China's CDMO capability is strongest in biologics (both mAb and biosimilar), viral vectors (particularly AAV, with substantial commercial-scale capacity via WuXi Advanced Therapies and others), and mRNA (rapid post-COVID capacity build). Small molecule and API manufacturing capacity is also substantial but sits outside CDMO Signal's primary coverage focus. Cross-reference with modality pages to filter Chinese CDMOs by capability: biologics, AAV, mRNA, or the viral vector umbrella. Individual profile pages surface facility-level detail.

Who are the top AAV / Gene Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include WuXi Biologics, uBriGene Biosciences, CoJourney Inc.. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many AAV / Gene Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 0 AAV / Gene Therapy CDMOs with FDA inspection records and 4 EMA/MHRA GMP certificates across the group.

What should I look for in an AAV CDMO?

Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.

What's the difference between AAV and lentiviral CDMOs?

AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.